Loading data for ABCL — first visit, this takes a few seconds.

알림

AbCellera Biologics Inc. (ABCL)

NasdaqGS: ABCL · 실시간 가격 · USD

11.12

-0.08 (-0.71%)

종가 기준: Aug 18, 2026, 8:00 PM

11.09

-0.27%

프리마켓: 8:06 AM

-0.71% (1D)

데이터 없음

매수호가	8.28
시가총액	3.41B
매출 (ttm)	66.17M
순이익 (ttm)	-164.66M
베타	1.19
EPS (ttm)	-0.54
P/E (ttm)	n/a
선행 P/E	-15.55
P/B (ttm)	3.80
P/S (ttm)	51.53
Earnings Date	Nov 5, 2026

매도호가	13.73
거래량	8,169,847
평균 거래량 (20일)	8,141,037
시가	10.90
전일 종가	11.20
일중 범위	10.70 - 11.52
52주 범위	2.75 - 11.64
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ABCL 소개

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 11, 2020

직원 수 562

상장 거래소 NasdaqGS

티커 ABCL

웹사이트 https://www.abcellera.com

전체 기업 정보

재무 실적

2025년 AbCellera Biologics의 매출은 75.13M로, 전년 28.83M 대비 160.56% 증가했습니다. 순이익은 -146.41M로, -10.1% 감소했습니다.

재무제표

어닝 서프라이즈

AbCellera Biologics가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $4.05M 예상치 하회 $0, 및 -76.29% 전년 대비 감소.

EPS -0.18 예상치 하회 -0.02, 및 -50.00% 전년 대비 감소.

다음 실적 발표

AbCellera Biologics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Insider Monkey

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial resul...

4일 전 · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

5일 전 · MT Newswires

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Producer Inflation Data Release

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

6일 전 · Motley Fool

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

1주 전 · Simply Wall St.

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...

2 페이지 중 1

AbCellera Biologics Inc. (ABCL)